Progress in immunotherapy for uveal melanoma
10.3760/cma.j.cn511434-20200207-00044
- VernacularTitle:葡萄膜黑色素瘤的免疫治疗进展
- Author:
Rui FANG
;
Yang LI
;
Wenbin WEI
- From:
Chinese Journal of Ocular Fundus Diseases
2021;37(4):327-332
- CountryChina
- Language:Chinese
-
Abstract:
Once uveal melanoma (UM) has distant metastasis, the median survival time of the patient is less than 12 months. There is currently a lack of standard treatment for metastatic UM. In recent years, immunotherapy is splendid in the field of oncology. Immune checkpoint therapy, cancer vaccine therapy and T cell adoptive therapy have been applied to UM therapy. However, most of the clinical effects are limited and the survival benefit is not high. The recent early research results of the new immunotherapeutic drug IMCgp100 are encouraging.
